Revolutionizing Medicines and Materials Discovery These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Actual results may differ materially from those described in the forward-looking statements and are subject to a variety of assumptions, uncertainties, risks and important factors that are beyond our control, including the demand for our so ...

Financial Performance - Total revenue reached $54.8 million, a 16% increase compared to the second quarter of 2024[10] - Software revenue grew by 15% to $40.5 million[10] - Drug discovery revenue increased by 19% to $14.2 million[10] - Cash and marketable securities increased by 21% to $462.3 million as of June 30, 2025[28] - Deferred revenue surged by 289% to $186.5 million[28] Guidance and Outlook - The company maintains its software growth and drug discovery revenue guidance[10] - Operating expenses are expected to be lower than in 2024[10] - Third-quarter software revenue is projected to be between $36 million and $40 million[10] - The company anticipates software revenue to increase by 10%–15% in 2025[31] - Drug discovery revenue is projected to be between $45 million and $50 million in 2025[31] Pipeline and Development - Initial Phase 1 data for SGR-1505 was presented in June, with strategic opportunities for clinical development being explored[11] - Initial Phase 1 data for SGR-2921 and SGR-3515 are expected in the fourth quarter of 2025[11]

Financial Performance (Q1 2025) - Total revenue reached $59.6 million, a 63% increase compared to $36.6 million in Q1 2024 [13, 28] - Software revenue grew to $48.8 million, a 46% increase from $33.4 million in Q1 2024 [13, 28] - Drug discovery revenue significantly increased to $10.7 million, a 237% increase compared to $3.2 million in Q1 2024 [13, 28] - Cash and marketable securities increased by 18% to $512.1 million as of March 31, 2025, compared to $435.7 million as of March 31, 2024 [28] - Deferred revenue, current and long term, increased by 265% to $210.0 million as of March 31, 2025, compared to $57.5 million as of March 31, 2024 [28] Financial Guidance (2025) - The company projects software revenue growth of 10% - 15% for the full year 2025 [13, 37] - Drug discovery revenue is expected to be between $45 million and $50 million for 2025 [13, 37] - Operating expense growth is anticipated to be less than 5% for 2025 [13, 37] - Software revenue for the second quarter of 2025 is projected to be in the range of $38 million to $42 million [13, 37] Proprietary Pipeline Milestones - Initial Phase 1 clinical data for SGR-1505 (MALT1) in R/R B-cell malignancies is expected in June 2025 [13, 40] - Initial Phase 1 clinical data for SGR-2921 (CDC7) in R/R AML/MDS is expected in the second half of 2025 [13, 40] - Initial Phase 1 clinical data for SGR-3515 (Wee1/Myt1) in solid tumors is expected in the second half of 2025 [13, 40]

Financial Performance - Total revenue for 4Q24 was $88.3 million, a 19% increase compared to $74.1 million in 4Q23[13, 23] - Software revenue for 4Q24 was $79.7 million, a 16% increase compared to $68.7 million in 4Q23[13, 23] - Drug discovery revenue for 4Q24 was $8.7 million, a 58% increase compared to $5.5 million in 4Q23[13, 23] - Total revenue for FY24 was $207.5 million, a 4.2% decrease compared to $216.7 million in FY23[13, 25] - Software revenue for FY24 was $180.4 million, a 13% increase compared to $159.1 million in FY23[13, 25] - Drug discovery revenue for FY24 was $27.1 million, a 53% decrease compared to $57.5 million in FY23[13, 25] 2025 Financial Guidance - The company expects software revenue growth of 10% - 15% in 2025[13, 43] - The company expects drug discovery revenue between $45 million and $50 million in 2025[13, 43] - The company expects operating expense growth to be less than 5% in 2025[13, 43] Key Performance Indicators - Total annual contract value (ACV) increased from $154.2 million in 2023 to $190.8 million in 2024[39] - The number of customers with ACV ≥$5M doubled from 4 in 2023 to 8 in 2024[39]